Oxford BioMedica TroVax Prostate Cancer Trial Approved

26th Jul 2010 07:32

LONDON (Dow Jones)--Biotechnology company Oxford BioMedica PLC (OXB.LN) Monday said it received approval to begin a clinical trial of its cancer vaccine TroVax in men with prostate cancer. Oxford BioMedica said the U.S. Food and Drug Administration approved plans to begin a Phase II trial of TroVax in 80 patients with prostate cancer who don't respond to hormone treatment. The study will compare treatment with TroVax and docetaxel, an older chemotherapy drug sold by Sanofi-Aventis SA (SAN.FR) as Taxotere, against treatment with docetaxel alone. It is scheduled to begin by the end of the third quarter, the company said. TroVax failed a trial in kidney cancer in 2008. It is being tested in other cancers, including mesothelioma, a cancer of the lung lining linked to asbestos exposure. -By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; [email protected] (END) Dow Jones Newswires July 26, 2010 02:32 ET (06:32 GMT)